Cargando…
The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens
Antiestrogens (AEs) are used to treat all stages of estrogen receptor (ER)-positive breast cancer. Selective estrogen receptor modulators such as tamoxifen have tissue-specific partial agonist activity, while selective estrogen receptor downregulators such as fulvestrant (ICI182,780) display a more...
Autores principales: | Vallet, Amandine, El Ezzy, Mohamed, Diennet, Marine, Haidar, Salwa, Bouvier, Michel, Mader, Sylvie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823126/ https://www.ncbi.nlm.nih.gov/pubmed/36460099 http://dx.doi.org/10.1016/j.jbc.2022.102757 |
Ejemplares similares
-
OR11-02 Structural Determinants of Pure Antiestrogenic Activity
por: Vallet, Amandine, et al.
Publicado: (2023) -
Antiestrogens: structure-activity relationships and use in breast cancer treatment
por: Traboulsi, T, et al.
Publicado: (2016) -
Estrogenic or antiestrogenic therapies for multiple myeloma?
por: Sola, Brigitte, et al.
Publicado: (2007) -
SUN-011 Identification Of Regulators Of Estrogenic Signalling In ER-positive Breast Cancer Cells By Whole Genome shRNA Screening
por: Kulpa, Justyna, et al.
Publicado: (2019) -
Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)